HIGH-DOSE CYTARABINE (HD-ARA-C) IN REFRACTORY AND RELAPSED ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)

被引：0
|
作者：
HOFELER, H [1 ]
ANDERS, CU [1 ]
POPESCU, O [1 ]
HOFFKEN, K [1 ]
SCHMIDT, CG [1 ]
机构：
[1] W GERMAN TUMOR CTR,ESEN,FED REP GER
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1987年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：209 / 209
页数：1
相关论文
共 50 条
  • [1] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
    Case, DC
    Ebrahim, KS
    Aronson, FR
    Hedlund, JA
    BLOOD, 2000, 96 (11) : 209B - 209B
  • [2] High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
    Cortes, J
    Estey, E
    O'Brien, S
    Giles, F
    Shen, Y
    Koller, C
    Beran, M
    Thomas, D
    Keating, M
    Kantarjian, H
    CANCER, 2001, 92 (01) : 7 - 14
  • [3] CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA (AML) REFRACTORY TO ANTHRACYCLINE CYTARABINE (ARA-C) THERAPIES
    KALWINSKY, D
    LOOK, AT
    MIRRO, J
    DAHL, GV
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 193 - 193
  • [4] HIGH-DOSE CYTARABINE IN ACUTE MYELOGENOUS LEUKEMIA
    ZITTOUN, R
    BONE MARROW TRANSPLANTATION, 1989, 4 : 38 - 42
  • [5] INTERMEDIATE-DOSE ARA-C M-AMSA FOR REMISSION INDUCTION AND HIGH-DOSE ARA-C M-AMSA FOR INTENSIVE CONSOLIDATION IN RELAPSED AND REFRACTORY ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
    JEHN, U
    HEINEMANN, V
    WILMANNS, W
    ANTICANCER RESEARCH, 1989, 9 (01) : 119 - 124
  • [6] Phase I study of a single high dose of liposomal daunorubicin combined with high dose cytarabine for adult patients with relapsed/refractory acute myelogenous leukemia (AML).
    Maslak, P
    Weiss, M
    Jurcic, J
    Cathcart, K
    Heaney, M
    Berman, E
    Soignet, S
    Scheinberg, D
    Ward, S
    BLOOD, 2000, 96 (11) : 325A - 325A
  • [7] HIGH-DOSE (HD) CYTOSINE-ARABINOSIDE (ARA-C) FOR THE TREATMENT OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOGENOUS LEUKEMIA (AML)
    HERZIG, GP
    WOLFF, SN
    HERZIG, RH
    STEIN, RS
    LAZARUS, HM
    MARION, JM
    SPTIZER, TR
    FLEXNER, JM
    PHILLIPS, GL
    LEUKEMIA RESEARCH, 1986, 10 (01) : 87 - 87
  • [8] Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
    Scappini, Barbara
    Gianfaldoni, Giacomo
    Caracciolo, Francesco
    Mannelli, Francesco
    Biagiotti, Caterina
    Romani, Claudio
    Pogliani, Enrico M.
    Simonetti, Federico
    Borin, Lorenza
    Fanci, Rosa
    Cutini, Ilaria
    Longo, Giovanni
    Susini, Maria Chiara
    Angelucci, Emanuele
    Bosi, Alberto
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : 1047 - 1051
  • [9] Cytogenetics predict complete remission rate (CR) for adult patients with de novo acute myelogenous leukemia (AML) treated with high dose cytarabine (HD ara-C).
    Stein, A
    ODonnell, MR
    Slovak, ML
    Lee, J
    Nademanee, A
    Parker, P
    Snyder, D
    Smith, E
    Molina, A
    Somlo, G
    Margolin, K
    Fahey, J
    Bierman, P
    Stepan, D
    Niland, J
    Blume, KG
    Forman, SJ
    BLOOD, 1997, 90 (10) : 277 - 277
  • [10] Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)
    Ulf Schnetzke
    Peter Fix
    Baerbel Spies-Weisshart
    Karin Schrenk
    Anita Glaser
    Hans-Joerg Fricke
    Paul La Rosée
    Andreas Hochhaus
    Sebastian Scholl
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1391 - 1397
12345